Show simple item record

dc.contributor.authorCaramori, Gaetano
dc.contributor.authorRuggeri, Paolo
dc.contributor.authorDi Stefano, Antonino
dc.contributor.authorMumby, Sharon
dc.contributor.authorGirbino, Giuseppe
dc.contributor.authorAdcock, Ian
dc.contributor.authorKirkham, Paul
dc.date.accessioned2017-11-28T12:01:23Z
dc.date.available2017-11-28T12:01:23Z
dc.date.issued2017-11-08
dc.identifier.citationCaramori G., Ruggeri P., Di Stefano A., Mumby S., et al (2017) 'Autoimmunity and COPD: clinical implications', Chest, 153(6), pp. 1424-1431 doi: 10.1016/j.chest.2017.10.033
dc.identifier.issn0012-3692
dc.identifier.pmid29126842
dc.identifier.doi10.1016/j.chest.2017.10.033
dc.identifier.urihttp://hdl.handle.net/2436/620904
dc.descriptionThis is an accepted manuscript of an article published by American College of Chest Physicians in Chest Journal on 07/11/2017, available online: https://doi.org/10.1016/j.chest.2017.10.033 The accepted version of the publication may differ from the final published version.en
dc.description.abstractChronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Long term cigarette smoking is the cause of more than 90% of COPD in Westernized countries. However, only a fraction of chronic heavy smokers develop symptomatic COPD by the age of 80 years. COPD is characterized by an abnormal immune response in the lower airways and its progression is associated with infiltration of the lung by innate and adaptive inflammatory immune cells that form lymphoid follicles. There is growing evidence that both cellular- and antibody-mediated autoimmunity has a fundamental role in the pathogenesis of stable COPD. In particular, carbonyl-modified proteins may help to drive autoimmunity in COPD and to cause the characteristic small airways abnormalities and even contribute to the pathogenesis of pulmonary emphysema. Although direct, indirect, and circumstantial evidence of a role for autoimmunity in stable COPD patients has been identified, no cause-and-effect relationship between autoimmunity and the mechanisms of COPD has been firmly established in man. As such the potential contribution of an autoimmune response to the pathogenesis of COPD exacerbation is still being investigated and represents an area of active research. Many drugs targeting autoimmune responses are already available and the results of controlled clinical trials are awaited with great interest. The potential for measuring specific serum autoantibodies as biomarkers to predict clinical phenotypes or progression of stable COPD is promising.
dc.language.isoen
dc.publisherElsevier
dc.relation.urlhttps://journal.chestnet.org/article/S0012-3692(17)33046-5/fulltext
dc.subjectADCC
dc.subjectBALT
dc.subjectautoantibody
dc.subjectautoimmunity
dc.subjectmAbs
dc.titleAutoimmunity and COPD: clinical implications.
dc.typeJournal article
dc.identifier.journalChest
dc.date.accepted2017-10-27
rioxxterms.funderJisc
rioxxterms.identifier.projectUOW281117PK
rioxxterms.versionAM
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
rioxxterms.licenseref.startdate2018-11-08
dc.source.volume153
dc.source.issue6
dc.source.beginpage1424
dc.source.endpage1431
refterms.dateFCD2018-10-19T09:24:44Z
refterms.versionFCDAM
refterms.dateFOA2018-11-07T00:00:00Z
html.description.abstractChronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Long term cigarette smoking is the cause of more than 90% of COPD in Westernized countries. However, only a fraction of chronic heavy smokers develop symptomatic COPD by the age of 80 years. COPD is characterized by an abnormal immune response in the lower airways and its progression is associated with infiltration of the lung by innate and adaptive inflammatory immune cells that form lymphoid follicles. There is growing evidence that both cellular- and antibody-mediated autoimmunity has a fundamental role in the pathogenesis of stable COPD. In particular, carbonyl-modified proteins may help to drive autoimmunity in COPD and to cause the characteristic small airways abnormalities and even contribute to the pathogenesis of pulmonary emphysema. Although direct, indirect, and circumstantial evidence of a role for autoimmunity in stable COPD patients has been identified, no cause-and-effect relationship between autoimmunity and the mechanisms of COPD has been firmly established in man. As such the potential contribution of an autoimmune response to the pathogenesis of COPD exacerbation is still being investigated and represents an area of active research. Many drugs targeting autoimmune responses are already available and the results of controlled clinical trials are awaited with great interest. The potential for measuring specific serum autoantibodies as biomarkers to predict clinical phenotypes or progression of stable COPD is promising.


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
PIIS0012369217330465.pdf
Size:
389.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/